Comparative Pharmacology
Head-to-head clinical analysis: TIGAN versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIGAN versus ZUPLENZ.
TIGAN vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
12-15 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic